Skip to Content
주식/증권 📉 부정적

This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

요약

Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.